A malaria vaccine based on a sporozoite antigen.

Malaria was eliminated from many temperate-zone countries in the 1940s, and in the next decade its prevalence was drastically reduced in several tropical countries. However, in recent years, this infection has undergone a resurgence in most tropical regions. Currently, malaria occurs in over 90 countries, and according to World Health Organization estimates, it causes up to 500 million clinical cases and 2.7 million deaths per year. Plasmodium falciparum is the most prevalent of the four malaria parasites of humans and causes most of the severe and lethal infections affecting young children and nonimmune adults. The P. vivax species also causes . . .

[1]  Joe D. Cohen,et al.  A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. , 1997, The New England journal of medicine.

[2]  A. García-Sastre,et al.  Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. , 1996, Cellular immunology.

[3]  D. Kyle,et al.  Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand , 1996, The Lancet.

[4]  S. Hoffman,et al.  Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity , 1996, The Journal of experimental medicine.

[5]  E. Nardin,et al.  The use of multiple antigen peptides in the analysis and induction of protective immune responses against infectious diseases. , 1995, Advances in immunology.

[6]  S. Hoffman,et al.  Protection against malaria by immunization with plasmid DNA encoding circumsporozoite protein. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[7]  P. Palese,et al.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  V. Nussenzweig,et al.  Rationale for the development of an engineered sporozoite malaria vaccine. , 1989, Advances in immunology.

[9]  V. Nussenzweig,et al.  Multiple T helper cell epitopes of the circumsporozoite protein of Plasmodium berghei , 1988, European journal of immunology.

[10]  Pedro Romero,et al.  A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria , 1988, Nature.

[11]  V. Nussenzweig,et al.  Synthetic peptide vaccine confers protection against murine malaria , 1987, The Journal of experimental medicine.

[12]  D. Clyde,et al.  Immunization of man against falciparum and vivax malaria by use of attenuated sporozoites. , 1975, The American journal of tropical medicine and hygiene.